Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsAntibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantThe V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Vaccines: past, present and future.Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloRhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesPrimate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsMacaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesHIV-1 vaccines and co-infection.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Problems and emerging approaches in HIV/AIDS vaccine development.Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaquesAlterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.Recombinant-attenuated Salmonella vaccines modified to reduce virulence.
P2860
Q27489000-4BAE2631-4FB5-4DE4-A927-0150CF4F218FQ28732438-ECC3A5C8-31DA-413F-9A96-93DA3F482CDEQ30381447-071D139F-BF3A-41C5-86B5-2E62D98CA7BAQ33558407-3D575906-98FA-41C4-BF9C-821E09066742Q33737723-031D2F40-6BC0-463C-9037-114965EA2D3FQ33877513-F4D4437D-B4CC-4AA8-85A0-49376823C4A9Q33883936-873935B0-D351-4211-BFB9-2CC139AD889AQ34120088-6DD2EDBD-A323-45E1-97A9-1486CE3B07DBQ34409178-DBD2469B-577E-4B17-A1AF-42B2E38493F0Q34982715-D3FB3946-87DC-4AC0-8E20-B1A75CB4240FQ35024202-D334C97D-FE14-4CFA-92A7-B5B4680861F8Q35024276-2F558D23-6E83-4B8A-AE8D-36443CE1D0FCQ35032794-0CDFA533-2E22-4A2A-A950-FB0EB89F65D8Q35169535-4EDD08F9-46DD-49C0-B2E4-9B9F379805ABQ35677724-F9BD590E-4BA0-4FDE-A124-391C8EBD5B3CQ35857254-B68E8A4C-5909-4D71-B9D2-32E73720818CQ35873784-2D1D9AAF-B659-4C25-A286-A54F1A92F6D1Q36138144-B1107150-E83B-4495-B829-6CA1A7783F6AQ36600380-1943ECA9-D605-4A8F-A0BB-5FC39C5694DFQ36758574-0A8ACED7-2B7C-4969-8234-A34B6DC93BBEQ37309980-5199B465-AC70-47B6-892D-C70B04258CC7Q38342167-28D8354E-BD1C-4341-946D-5D64C387F407Q40051843-A3B0DF33-AB47-4D07-A60C-E979EE5525AAQ50035660-97C65A31-D415-4B1C-8F8E-5965B8C494C7
P2860
Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Priming B cell-mediated anti-H ...... s exposed to a R5-tropic SHIV.
@en
type
label
Priming B cell-mediated anti-H ...... s exposed to a R5-tropic SHIV.
@en
prefLabel
Priming B cell-mediated anti-H ...... s exposed to a R5-tropic SHIV.
@en
P2093
P1433
P1476
Priming B cell-mediated anti-H ...... es exposed to a R5-tropic SHIV
@en
P2093
Agegnehu Gettie
Cheryl J Saunders
Clarisa Buckner
Indresh Srivastava
James Blanchard
Jeffrey T Safrit
Leoned G Gines
Leonidas Stamatatos
Rudolph Bohm
Susan W Barnett
P304
P356
10.1016/J.VIROL.2003.12.003
P407
P577
2004-03-01T00:00:00Z